Please login to the form below

Not currently logged in
Email:
Password:

SGLT2

This page shows the latest SGLT2 news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

J&J’s Invokana first SGLT2 to show kidney disease benefits

The results from the phase 3 CREDENCE study are an important boost for Invokana, which is trailing behind other competitors in the SGLT2 inhibitor class in terms of market share. ... The trial puts Invokana one step ahead of rivals, such as AstraZeneca,

Latest news

  • Success for AZ, setback for Sanofi in type 1 diabetes Success for AZ, setback for Sanofi in type 1 diabetes

    The approval means AZ’s SGLT2 inhibitor Forxiga (dapagliflozin) can be used in the EU in overweight or obese type 1 diabetes patients who are struggling to keep control of their ... Sanofi has been less fortunate with its US marketing application for

  • Trulicity’s ascent lifts Lilly Trulicity’s ascent lifts Lilly

    filing. Also performing well in its diabetes franchise is Jardiance, the oral SGLT2 inhibitor treatment increasing revenues by 47% over the year to $658.3m.

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    AZ claims first with Forxiga in type 1 diabetes. Among the usual crop of line extensions, AZ’s SGLT2 inhibitor Forxiga (dapagliflozin) became the first oral add-on treatment to insulin ... The drug is also under regulatory review for this indication in

  • FDA adcomm split on Sanofi’s type 1 diabetes drug FDA adcomm split on Sanofi’s type 1 diabetes drug

    Sanofi and partner Lexicon Pharma have developed the orally-active SGLT1 and SGLT2 inhibitor for this indication on the grounds that it could help type 1 diabetes who struggle to control ... Current SGLT2-selective drugs – such as Johnson &Johnson’s

  • Lilly trumpets Trulicity heart data in face-off with Novo Nordisk Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

    Boehringer Ingelheim and Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) was the first drug approved by the FDA as being able to reduce the risk of cardiovascular death in patients with type ... products. The LEADER trial of Victoza also showed a 13%

More from news
Approximately 9 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Figure 1 (pictured right) shows the position of the DPP4/SGLT2 market for the last four months to March 2017 in English GP practices compared to the previous Tertial (four months). ... In contrast Jardiance and Vipidia are still growing where Jardiance

  • Deal Watch November 2015 Deal Watch November 2015

    Sotagliflozin is an oral dual inhibitor of sodium-glucose cotransporters type 1 and 2 (SGLT1 &SGLT2) which are responsible for glucose reabsorption by the GI tract and kidney respectively.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics